Citigroup Inc Apellis Pharmaceuticals, Inc. Call Options Transaction History

Citigroup Inc

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 10, 2024	BUY	$55.39 - $72.47 $4.97 Million - $6.5 Million	89,700 New	89,700 $5.27 Million
Q3 2023 Nov 09, 2023	BUY	$23.65 - $89.22 $236,500 - $892,200	10,000 Added 50.0%	30,000 $1.14 Million
Q2 2023 Aug 10, 2023	SELL	$76.68 - $93.31 $375,732 - $457,219	-4,900 Reduced 19.68%	20,000 $1.82 Million
Q1 2023 May 11, 2023	BUY	$46.59 - $66.96 $9,318 - $13,391	200 Added 0.81%	24,900 $1.64 Million
Q4 2022 Feb 09, 2023	SELL	$43.24 - $61.04 $445,372 - $628,712	-10,300 Reduced 29.43%	24,700 $1.28 Million
Q3 2022 Nov 10, 2022	BUY	$44.76 - $69.66 $1.32 Million - $2.05 Million	29,400 Added 525.0%	35,000 $2.39 Million
Q2 2022 Aug 10, 2022	SELL	$35.07 - $59.21 $231,462 - $390,786	-6,600 Reduced 54.1%	5,600 $253,000
Q1 2022 May 12, 2022	BUY	$35.46 - $54.12 $432,612 - $660,264	12,200 New	12,200 $620,000

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.